title: Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
abstract: Alzheimer's disease (AD) is characterized by enhanced beta-amyloid peptide (betaA) deposition along with glial activation in senile plaques, selective neuronal loss, and cognitive deficits. Cannabinoids are neuroprotective agents against excitotoxicity in vitro and acute brain damage in vivo. This background prompted us to study the localization, expression, and function of cannabinoid receptors in AD and the possible protective role of cannabinoids after betaA treatment, both in vivo and in vitro. Here, we show that senile plaques in AD patients express cannabinoid receptors CB1 and CB2, together with markers of microglial activation, and that CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microglial activation. In pharmacological experiments, we found that G-protein coupling and CB1 receptor protein expression are markedly decreased in AD brains. Additionally, in AD brains, protein nitration is increased, and, more specifically, CB1 and CB2 proteins show enhanced nitration. Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent betaA-induced microglial activation, cognitive impairment, and loss of neuronal markers. Cannabinoids (HU-210, WIN55,212-2, and JWH-133) block betaA-induced activation of cultured microglial cells, as judged by mitochondrial activity, cell morphology, and tumor necrosis factor-alpha release; these effects are independent of the antioxidant action of cannabinoid compounds and are also exerted by a CB2-selective agonist. Moreover, cannabinoids abrogate microglia-mediated neurotoxicity after betaA addition to rat cortical cocultures. Our results indicate that cannabinoid receptors are important in the pathology of AD and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease.
authors.affiliation: Neurodegeneration Group, Cajal Institute, Consejo Superior de Investigaciones Científicas, 28002 Madrid, Spain.
authors.forename: Belén G
authors.initials: BG
authors.lastname: Ramírez
authors.forename: Cristina
authors.initials: C
authors.lastname: Blázquez
authors.forename: Teresa
authors.initials: T
authors.lastname: Gómez del Pulgar
authors.forename: Manuel
authors.initials: M
authors.lastname: Guzmán
authors.forename: María L
authors.initials: ML
authors.lastname: de Ceballos
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000503:physiopathology / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000378:metabolism / Q000633:toxicity; D000818:Animals; D048588:Benzoxazines; D002186:Cannabinoids / Q000008:administration & dosage / Q000494:pharmacology*; D002478:Cells, Cultured / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D018920:Coculture Techniques; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D017628:Microglia / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009281:Naphthalenes / Q000008:administration & dosage / Q000494:pharmacology*; D009410:Nerve Degeneration / Q000517:prevention & control; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D009569:Nitric Oxide / Q000378:metabolism; D010446:Peptide Fragments / Q000633:toxicity; D058225:Plaque, Amyloid / Q000187:drug effects* / Q000378:metabolism; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists* / Q000502:physiology; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D048588:Benzoxazines; D002186:Cannabinoids; C469526:Cnr2 protein, rat; D009025:Morpholines; D009281:Naphthalenes; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D014409:Tumor Necrosis Factor-alpha; C074636:amyloid beta-protein (25-35); D009569:Nitric Oxide; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D013759:Dronabinol; C062018:HU 211; C432747:1,1-dimethylbutyl-1-deoxy-Delta(9)-THC
references.citation: J Pharmacol Exp Ther. 1999 Mar;288(3):1357-66
references.pmid: 10027878
references.citation: J Med Chem. 1999 Feb 25;42(4):769-76
references.pmid: 10052983
references.citation: J Neurosci. 1999 Apr 15;19(8):2987-95
references.pmid: 10191316
references.citation: Neuroscience. 1999;92(4):1177-91
references.pmid: 10426477
references.citation: J Neuropathol Exp Neurol. 1999 Nov;58(11):1163-9
references.pmid: 10560659
references.citation: Glia. 2000 Jan 1;29(1):58-69
references.pmid: 10594923
references.citation: Neurosci Lett. 2000 Jan 7;278(1-2):69-72
references.pmid: 10643803
references.citation: Bioorg Med Chem. 1999 Dec;7(12):2905-14
references.pmid: 10658595
references.citation: Ann Neurol. 2000 Apr;47(4):524-7
references.pmid: 10762167
references.citation: Neuroscience. 2000;97(3):505-19
references.pmid: 10828533
references.citation: Neurobiol Aging. 2000 May-Jun;21(3):383-421
references.pmid: 10858586
references.citation: Nat Med. 2000 Aug;6(8):916-9
references.pmid: 10932230
references.citation: Neurobiol Dis. 2000 Aug;7(4):429-47
references.pmid: 10964613
references.citation: J Neurosci. 2000 Oct 15;20(20):7587-94
references.pmid: 11027218
references.citation: Eur J Neurosci. 2001 Apr;13(8):1529-36
references.pmid: 11328347
references.citation: Nat Med. 2001 May;7(5):612-8
references.pmid: 11329064
references.citation: Mol Pharmacol. 2001 Jul;60(1):155-63
references.pmid: 11408610
references.citation: Neuroscience. 2001;104(3):609-13
references.pmid: 11440793
references.citation: Cancer Res. 2001 Aug 1;61(15):5784-9
references.pmid: 11479216
references.citation: J Neurosci. 2001 Sep 1;21(17):6475-9
references.pmid: 11517236
references.citation: Nature. 2001 Oct 4;413(6855):527-31
references.pmid: 11586361
references.citation: J Neurosci. 2002 Feb 1;22(3):782-90
references.pmid: 11826108
references.citation: Brain Res. 2002 Feb 22;928(1-2):76-84
references.pmid: 11844474
references.citation: Neuroscience. 2002;110(1):49-58
references.pmid: 11882372
references.citation: J Neurosci. 2002 Mar 15;22(6):2246-54
references.pmid: 11896164
references.citation: J Neurochem. 2002 Feb;80(3):448-56
references.pmid: 11905991
references.citation: J Neurosci. 2002 May 1;22(9):3484-92
references.pmid: 11978825
references.citation: Pharmacol Rev. 2002 Jun;54(2):161-202
references.pmid: 12037135
references.citation: Neurosci Lett. 2002 Jun 14;325(3):199-202
references.pmid: 12044655
references.citation: J Biol Chem. 2002 Sep 27;277(39):36527-33
references.pmid: 12133838
references.citation: Neurosci Lett. 2002 Oct 31;332(2):127-30
references.pmid: 12384227
references.citation: Nat Neurosci. 2002 Nov;5 Suppl:1058-61
references.pmid: 12403986
references.citation: J Neurosci. 2002 Nov 15;22(22):9742-53
references.pmid: 12427829
references.citation: J Neurosci. 2002 Nov 15;22(22):9771-5
references.pmid: 12427832
references.citation: Glia. 2003 Jan 15;41(2):161-8
references.pmid: 12509806
references.citation: J Neurosci. 2003 Feb 15;23(4):1398-405
references.pmid: 12598628
references.citation: Science. 2003 Oct 3;302(5642):84-8
references.pmid: 14526074
references.citation: Nat Rev Neurosci. 2003 Nov;4(11):873-84
references.pmid: 14595399
references.citation: J Neurosci. 2003 Dec 3;23(35):11136-41
references.pmid: 14657172
references.citation: Neurosci Lett. 1992 Dec 7;147(2):179-81
references.pmid: 1491804
references.citation: Neuropharmacology. 2004 Apr;46(5):716-26
references.pmid: 14996549
references.citation: Neurobiol Dis. 2004 Apr;15(3):580-9
references.pmid: 15056466
references.citation: Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
references.pmid: 2308954
references.citation: Am J Pathol. 1988 Jul;132(1):86-101
references.pmid: 2456021
references.citation: Neurosci Lett. 1987 Aug 18;79(1-2):195-200
references.pmid: 3670729
references.citation: J Cell Biol. 1980 Jun;85(3):890-902
references.pmid: 6248568
references.citation: Mol Pharmacol. 1995 Sep;48(3):443-50
references.pmid: 7565624
references.citation: Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9328-32
references.pmid: 7568127
references.citation: Nature. 1995 Apr 13;374(6523):647-50
references.pmid: 7715705
references.citation: J Biol Chem. 1995 Jun 9;270(23):13973-80
references.pmid: 7775459
references.citation: Neuroscience. 1994 Dec;63(3):637-52
references.pmid: 7898667
references.citation: Cell. 1994 Dec 2;79(5):755-65
references.pmid: 8001115
references.citation: FEBS Lett. 1994 Aug 22;350(2-3):240-4
references.pmid: 8070571
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3984-9
references.pmid: 8633002
references.citation: J Neurosci. 1996 Sep 15;16(18):5795-811
references.pmid: 8795633
references.citation: J Exp Med. 1996 Oct 1;184(4):1425-33
references.pmid: 8879214
references.citation: Eur J Pharmacol. 1997 Jan 14;319(1):1-4
references.pmid: 9030890
references.citation: J Neurosci. 1997 Apr 15;17(8):2653-7
references.pmid: 9092586
references.citation: J Pharmacol Exp Ther. 1997 Sep;282(3):1632-42
references.pmid: 9316881
references.citation: Am J Pathol. 1998 Jan;152(1):307-17
references.pmid: 9422548
references.citation: J Pharmacol Exp Ther. 1998 Feb;284(2):644-50
references.pmid: 9454810
references.citation: Neuroscience. 1997 Mar;77(2):299-318
references.pmid: 9472392
references.citation: J Neurosci. 1998 Mar 15;18(6):2161-73
references.pmid: 9482801
references.citation: Neuroscience. 1998 Jun;84(4):1075-83
references.pmid: 9578396
references.citation: Neurobiol Aging. 1998 May-Jun;19(3):201-4
references.pmid: 9661994
references.citation: Br J Pharmacol. 1998 Jun;124(4):619-22
references.pmid: 9690851
references.citation: Mol Pharmacol. 1998 Sep;54(3):459-62
references.pmid: 9730904
references.citation: FEBS Lett. 1998 Sep 25;436(1):6-10
references.pmid: 9771884
references.citation: Microsc Res Tech. 1998 Oct 1;43(1):75-88
references.pmid: 9829462